Blueprint Medicines has entered into a global licensing and collaboration agreement with Roche to develop and commercialise pralsetinib for the treatment of RET-altered cancers. The deal, which is worth upto US$1.7 B, marks the second alliance between the two companies following a March 2016 agreement to develop and commercialise up to five kinase-targeting immunotherapies; to date, one target has been announced under the collaboration: MAP4K1.